Jacqueline G. O'Leary, S. Michelle Shiller, Christopher Bellamy, Michael A. Nalesnik, Hugo Kaneku, Linda W. Jennings, Kumiko Isse, Paul I. Terasaki, Göran B. Klintmalm, Anthony J. Demetris – 6 July 2014 – Acute antibody‐mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a generalizable scoring system and (2) to trigger a more in‐depth analysis are needed to screen for this rare but important finding.

Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones – 5 July 2014 – Cardiovascular disease (CVD) contributes to excessive long‐term mortality after liver transplantation (LT); however, little is known about early postoperative CVD mortality in the current era. In addition, there is no model for predicting early postoperative CVD mortality across centers.

Emily Rothbaum Perito, Philip Rosenthal – 5 July 2014

Aparna Goel, Neil Mehta, Jennifer Guy, Nicholas Fidelman, Francis Yao, John Roberts, Norah Terrault – 5 July 2014 – Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down‐stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT.

Jasmine Kouz, Catherine Vincent, Aaron Leong, Marc Dorais, Agnès Räkel – 5 July 2014 – Posttransplant weight gain is common after orthotopic liver transplantation. We sought to determine the extent of weight gain at 5 years after transplantation in patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis versus patients with other types of cirrhosis (non‐NAFLD). We studied 126 liver transplants performed between 2005 and 2007 at Saint Luc Hospital, University of Montreal. Seventeen of the 126 patients (13.5%) had NAFLD cirrhosis.

Susan Holtzman, Hance A. Clarke, Stuart A. McCluskey, Kara Turcotte, David Grant, Joel Katz – 5 July 2014 – Despite its prominence as a concern among potential surgical candidates, there is little information in the literature regarding the short‐ and long‐term pain experience after living liver donation. We undertook a prospective study to examine (1) the nature and incidence of acute and chronic pain after living donor hepatectomy and (2) the factors associated with an increased or decreased risk of adverse pain outcomes.

Liping Chen, Geng Chen, Yibin Guo, Lei Liu, Li Xiao, Wenmei Fan, Bingyi Shi, Yeyong Qian – 5 July 2014 – Biliary fibrosis is a major complication after donation after cardiac death (DCD) liver transplantation. In this process, the roles of serotonin [5‐hydroxytryptamine (5‐HT)] and the 5‐HT2A receptor subtype are still unknown.

Michal Pawlak, Eric Baugé, William Bourguet, Karolien Bosscher, Fanny Lalloyer, Anne Tailleux, Corinna Lebherz, Philippe Lefebvre, Bart Staels – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated with central obesity, dyslipidemia, and insulin resistance.

Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean‐Frederic Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won‐Young Tak, Xiaoping Yu, Joon‐Hyeok Lee, Shi‐Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian B. Walters, Christine Dela Cruz, Valerie Poulart, Jian‐Hua Wang – 4 July 2014 – Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate‐stage hepatocellular carcinoma (HCC).

Eleonora Scorletti, Lokpal Bhatia, Keith G. McCormick, Geraldine F. Clough, Kathryn Nash, Leanne Hodson, Helen E. Moyses, Philip C. Calder, Christopher D. Byrne, on behalf of the WELCOME Study Investigators – 4 July 2014 – There is no licensed treatment for nonalcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes, and cardiovascular disease.